Repository logo
 
Publication

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab

2019Journal article Open access
Simple item page
dc.contributor.authorMagro, Fernando
dc.contributor.authorLopes, Susana
dc.contributor.authorSilva, Marco
dc.contributor.authorCoelho, Rosa
dc.contributor.authorPortela, Francisco
dc.contributor.authorBranquinho, Diogo
dc.contributor.authorCorreia, Luís
dc.contributor.authorFernandes, Samuel
dc.contributor.authorCravo, Marília
dc.contributor.authorCaldeira, Paulo
dc.contributor.authorSousa, Helena Tavares
dc.contributor.authorPatita, Marta
dc.contributor.authorLago, Paula
dc.contributor.authorRamos, Jaime
dc.contributor.authorAfonso, Joana
dc.contributor.authorRedondo, Isabel
dc.contributor.authorMachado, Patrícia
dc.contributor.authorPhilip, George
dc.contributor.authorLopes, Joanne
dc.contributor.authorCarneiro, Fátima
dc.date.accessioned2019-10-08T13:03:01Z
dc.date.available2019-10-08T13:03:01Z
dc.date.issued2019
dc.description.abstractSuppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.pt_PT
dc.description.sponsorshipAgência financiadora Merck Sharp and Dohme, Lda, Portugal MK8259-22pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1177/1756284819869141
dc.identifier.urihttp://hdl.handle.net/10400.1/12800
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSAGE Publicationspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectEndoscopic activitypt_PT
dc.subjectGolimumabpt_PT
dc.subjectHistological activitypt_PT
dc.subjectSerum soluble ST2pt_PT
dc.subjectUlcerative colitispt_PT
dc.titleSoluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPageUNSP 1756284819869141pt_PT
oaire.citation.titleTherapeutic Advances in Gastroenterologypt_PT
oaire.citation.volume12pt_PT
person.familyNameCaldeira
person.familyNameSousa
person.givenNamePaulo
person.givenNameHelena Tavares
person.identifier.ciencia-id1112-F0B2-19A3
person.identifier.ciencia-idCF1F-1163-1C4A
person.identifier.orcid0000-0002-2404-6295
person.identifier.orcid0000-0002-6626-205X
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3def3720-8982-4c46-801d-af640d508b59
relation.isAuthorOfPublication6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e
relation.isAuthorOfPublication.latestForDiscovery6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1177_1756284819869141.pdf
Size:
910.65 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)
ULS2-Artigos (em revistas ou actas indexadas)
ULS_10.1-MED-Artigos